Although we were unable to obtain direct supporting evidence for chemotherapy-induced RRM2-to-RRM2B switch in primary patient tumors due to the lack of clinical resources, our data are consistent with the notion that RRM2B is the dominant RNR M2 subunit in chemotherapy-treated HB patient tumors. This evidence concerns the gene NR2E3 and hemoglobin measurement.